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The cardiac T-box transcription factor TBX5 is crucial for proper cardiovascular development, and mu-
tations in TBX5 have been associated with various congenital heart diseases and arrhythmias in humans.
However, whether mutated TBX5 contributes to dilated cardiomyopathy (DCM) remains unclear. In this
study, the coding exons and ﬂanking introns of the TBX5 gene were sequenced in 190 unrelated patients
with idiopathic DCM. The available family members of the index patient carrying an identiﬁed mutation
and 200 unrelated ethnically matched healthy individuals used as controls were genotyped for TBX5. The
functional characteristics of the mutant TBX5 were explored in contrast to its wild-type counterpart by
using a dual-luciferase reporter assay system. As a result, a novel heterozygous TBX5 mutation, p.S154A,
was identiﬁed in a family with DCM inherited in an autosomal dominant pattern, which co-segregated
with DCM in the family with complete penetrance. The missense mutation was absent in 400 control
chromosomes and the altered amino acid was completely conserved evolutionarily across various spe-
cies. Functional assays revealed that the mutant TBX5 had signiﬁcantly decreased transcriptional activity.
Furthermore, the mutation markedly diminished the synergistic activation of TBX5 with NKX2-5 or
GATA4, other two transcription factors causatively linked to DCM. This study ﬁrstly associates TBX5 loss-
of-function mutation with enhanced susceptibility to DCM, providing novel insight into the molecular
mechanisms of DCM, and suggesting the potential implications in the development of new treatment
strategies for this common form of myocardial disorder.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dilated cardiomyopathy (DCM), characterized by progressive
ventricular dilatation and systolic dysfunction in the absence of
associated conditions such as hypertension, valvular heart disease
and coronary artery disease, is the most prevalent type of primary
myocardial disease, affecting approximately 1 in 250 persons [1]. Ity, Shanghai Chest Hospital,
d, Shanghai 200030, China.
y, Shanghai Tenth People's
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. Xu), dryyq@tongji.edu.cn
Inc. This is an open access article uis one of the most frequent causes of congestive heart failure and is
the commonest reason for cardiac transplantation in adults and
children [2]. In majority of patients, DCM occurs sporadically, but in
25%e35% of cases, familial transmission of DCM is observed in an
autosomal dominant, recessive, or X-linked pattern with variable
expressivity and penetrance [3]. Increasing evidence demonstrates
that genetic defects play an important role in the pathogenesis of
DCM, and a great number of mutations in more than 50 genes have
been associated with DCM. Of these well established DCM-
associated genes, most code for cardiac structural or regulatory
proteins, including myocardial sarcomeric and cytoskeletal pro-
teins [1]. However, DCM is a genetically heterogeneous disorder,
and the genetic determinants underpinning DCM in a signiﬁcant
proportion of patients remain unknown.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primer pairs used to amplify the coding exons and ﬂanking introns of the TBX5 gene.
Coding
exon
Forward primer (50 to 30) Reverse primer (50 to 30) Size
(bp)
1 TGGAAACTGGGGGCCAAACT TCTGTCCCCGCAAGAGAAGC 385
2 TTGGGGAAGGAATGCCCACT ATCCAGATAGCACGGCCTCC 470
3 TACCTACAGTTGCCCGCCTG GATAGGCGGACAGACGCCTT 477
4 CAGTGCGCTACCTCCAGACT GGTAGAGGCAGAAAGCGACGA 359
5 ACCCTGGCTTTTTCGGTTGG CACCCTGGGGTCGAAGTTGG 487
6 GGGCAAACCAAACCCAGGTG GGGACAGAGGGGGCTCATTC 477
7 CACACCTGGTTCAGCCACTC CACCCCCAACCCAAGGAAAG 369
8 CACTTTTAGCTGCCTGGTGCC AGGAAATGTCTGTTGTGAAGCAGG 665
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factors, including the homeodomain protein NKX2-5, zinc ﬁnger
proteins GATA4, GATA5, and GATA6, and T-box factors TBX1, TBX2,
TBX3, TBX4, TBX5, TBX18 and TBX20, play a crucial role in the
normal cardiovascular development [4]. These core transcription
factors physically interact with each other and with an array of
other transcription factors, and function in a mutually reinforcing
transcriptional network to ﬁnely control heart development [4].
Hence, it is not surprising that mutations inmost of the core cardiac
transcription factors, especially for the most extensively studied
cardiac transcription factors NKX2-5, GATA4 and TBX5, have been
associated with non-synodromic or synodromic congenital heart
diseases as well as arrhythmias [4e22]. Interestingly, mutations in
some cardiac transcription factors, such as NKX2-5, GATA4, GATA6
and TBX20, have also been causally linked to DCM in humans
[23e28]. Given that the expression proﬁle and functional charac-
teristics of TBX5 overlap at least partially with those of NKX2-5,
GATA4, GATA6 and TBX20 [29e31], it is warranted to make the hy-
pothesis that mutated TBX5 may contribute to DCM in a subset of
patients.
2. Materials and methods
2.1. Study subjects
In this study, a cohort of 190 unrelated patients with DCM was
enrolled from the Han Chinese population. The available family
members of the index patients were also recruited. A total of 200
ethnically-matched unrelated healthy individuals from a routine
physical examination were enlisted as controls. All participants un-
derwent clinical evaluation, chest radiography, electrocardiogram,
echocardiography and exercise capacity testing. Cardiac catheteri-
zation, coronary angiography, endomyocardial biopsy or cardiac
magnetic resonance imaging was performed only if there was a
strong clinical indication. The clinical diagnosis of DCMwas made in
accordance with the criteria established by the World Health Or-
ganization/International Society and Federation of Cardiology Task
Force on the Classiﬁcation of Cardiomyopathy: a left ventricular end-
diastolic diameter >27 mm/m2 and an ejection fraction <40% or
fractional shortening <25% in the absence of an apparent secondary
cause of cardiomyopathy, such as ischemic heart disease, valvular
heart disease, essential hypertension, viral myocarditis and cardiac
glycogen storage disease [32]. Familial DCMwas deﬁned as the DCM
occurring in two or more ﬁrst-degree relatives of a family. This
investigation conformed to the principles of the Declaration of
Helsinki. The study protocol was reviewed and approved by the local
institutional ethics committee. Written informed consent was ob-
tained from all the participants prior to study.
2.2. Screening for TBX5 mutation
Peripheral venous blood samples were taken from all the study
participants. Genomic DNA was puriﬁed from blood leukocytes of
each participant with Wizard Genomic DNA Puriﬁcation Kit (Prom-
ega, Madison, WI, USA). The referential genomic DNA sequence of
TBX5 derived from GenBank (accession no. NG_007373.1). The
primers used to amplify the coding exons and intron/exon bound-
aries of TBX5 by polymerase chain reaction (PCR) were designed as
shown in Table 1. Ampliﬁcation of genomic DNA fragment by PCR
was carried out using HotStar Taq DNA Polymerase (Qiagen, Hilden,
Germany) on a Veriti Thermal Cycler (Applied Biosystems, Foster, CA,
USA) with standard conditions and concentrations of reagents. Both
strands of each amplicon were sequenced with a BigDye® Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems) under an ABI
PRISM 3130 XL DNA Analyzer (Applied Biosystems). For everyidentiﬁed sequence variant, the single nucleotide polymorphism
(SNP; http://www.ncbi.nlm.nih.gov/SNP) and Exome Variant Server
(EVS; http://evs.gs.washington.edu/EVS) databases were queried to
conﬁrm its novelty.
2.3. Alignment of multiple TBX5 protein sequences across species
Multiple TBX5 protein sequences from various species were
aligned using the online MUSCLE program, version 3.6 (http://
www.ncbi.nlm.nih.gov/).
2.4. Expression plasmids and site-directed mutagenesis
Human TBX5 containing the whole coding sequence was pro-
duced by PCR ampliﬁcation using the human full-length cDNAs
prepared previously [12], digested with EcoRI and NotI, and sub-
sequently cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad,
CA, USA). The identiﬁed mutation was introduced into the wild-
type TBX5-pcDNA3.1 construct by PCR-based site-directed muta-
genesis using a QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) and veriﬁed by sequencing. The
expression plasmids NKX2-5-pEFSA, GATA4-pSSRa and ANF-
luciferase reporter (ANF-luc), which contains the 2600-bp 50-
ﬂanking region of the ANF gene and expresses the Fireﬂy luciferase,
were kind gifts provided by Dr. Ichiro Shiojima at Chiba University
School of Medicine, Japan.
2.5. Luciferase reporter gene assays
COS-7 cellswere cultured inDulbecco'smodiﬁed Eagle'smedium
supplemented with 10% fetal calf serum, and maintained in a hu-
midiﬁed atmosphere with 5% CO2. Lipofectamine® 2000 reagent
(Invitrogen) was used for transfection of COS-7 cells at about 80%
conﬂuency. The internal control vector pGL4.75 (hRluc/CMV, Prom-
ega) expressing the Renilla luciferase was used in transient trans-
fection assays to normalize transfection efﬁciency. In each
transfection, the same amount (0.6 mg) of expression plasmid DNA
(wild-type TBX5-pcDNA3.1, NKX2-5-pEFSA, GATA4-pSSRaormutant
TBX5-pcDNA3.1) was used alone or together, in combination with
1.0 mg of ANF-luc and 0.04 mg of pGL4.75. Cells were harvested 48 h
after transfection, and the Fireﬂy and Renilla luciferase activities
weremeasuredwith theDual-Glo luciferase assay system(Promega).
The activity of the ANF promoter was presented as fold activation of
Fireﬂy luciferase relative to Renilla luciferase. Three independent
experiments were performed at minimum for each transfection.
2.6. Statistical analysis
Statistical software package SPSS (version 15.0) was used for
statistical analysis. Data are expressed as mean ± SD. Differences
betweenmeans were compared using the Student's unpaired t test.
Comparison of the categorical variables between two groups was
Table 2
The baseline clinical characteristics of the study population.
Variables Patients (n ¼ 190) Controls (n ¼ 200)
Age (years) 56 ± 12 57 ± 11
Male (%) 92 (48) 100 (50)
Positive family history of DCM (%) 68 (36) 0 (0)
SBP (mmHg) 117 ± 15 120 ± 12
DBP (mmHg) 78 ± 8 80 ± 6
LVEDD (mm) 68 ± 7 46 ± 6
LVESD (mm) 55 ± 8 34 ± 5
LVEF (%) 39 ± 9 63 ± 4
LVFS (%) 18 ± 6 31 ± 6
NYHA function class (%)
I 39 (21) NA
II 67 (35) NA
III 61 (32) NA
IV 23 (12) NA
DCM indicates dilated cardiomyopathy; SBP, systolic blood pressure; DBP, diastolic
blood pressure; LVEDD, left ventricular end-diastolic diameter; LVESD, left ven-
tricular end-systolic diameter; LVEF, left ventricular ejection fraction; LVFS, left
ventricular fractional shortening; NYHA, New York Heart Association; and NA, not
applicable.
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considered statistically signiﬁcant.
3. Results
3.1. Clinical characteristics of the study subjects
In this study, a total of 190 unrelated patients with DCM were
clinically investigated in contrast to 200 control individuals. All theFig. 1. A novel TBX5 mutation associated with dilated cardiomyopathy. A, sequence electr
control. The arrow indicates the heterozygous nucleotides of T/G in the proband (mutant)
type). The rectangle marks the nucleotides comprising a codon of TBX5. B, schematic diagram
The mutation identiﬁed in patients with dilated cardiomyopathy is shown above the T-box s
structure of the family with dilated cardiomyopathy. Family members are identiﬁed by gen
symbol with a slash, the deceased member; closed symbol, affected member; open sym
mutation; and “”, non-carrier.patients presented with typical DCM phenotype as described pre-
viously [32], and had no apparent secondary cause of DCM. The
control individuals had normal echocardiographic results without
evidence of structural cardiac diseases. The baseline clinical char-
acteristics of the study population are given in Table 2.
3.2. Identiﬁcation of a novel TBX5 mutation
Direct PCR-sequencing of the TBX5 gene led to the identiﬁcation
of a heterozygous mutation in 1 out of 190 unrelated patients with
DCM, with a mutational prevalence of roughly 0.53%. Speciﬁcally, a
substitution of guanine (G) for thymine (T) in the ﬁrst nucleotide of
codon 154 (c.460T > G), predicting the replacement of serine (S) by
alanine (A) at amino acid position 154 (p.S154A), was identiﬁed in a
patient with positive family history of DCM. The DNA sequencing
electropherograms showing the detected heterozygous TBX5 mu-
tation of c.460T > G compared with its control sequence are shown
in Fig. 1A. A schematic diagram of TBX5 showing the T-box struc-
tural domain and location of the mutation identiﬁed in this study is
presented in Fig. 1B. The missense mutation was neither found in
the control individuals nor reported in the SNP and EVS databases.
Genetic screening of the index patient's family members showed
that the mutation was present in all the affected living family
members, but absent in unaffected family members examined.
Analysis of the pedigree revealed that the mutation co-segregated
with DCM transmitted in an autosomal dominant mode in the
family with complete penetrance. Besides, the proband's two
younger sisters (II-6 and II-8) had also secundum atrial septal
defect and second-degree atrioventricular conduction block. The
pedigree structure of the family is illustrated in Fig. 1C. Theopherograms showing the heterozygous TBX5 mutation compared with its wild-type
or the homozygous nucleotides of T/T in the corresponding control individual (wild-
of TBX5 protein structure with the dilated cardiomyopathy related mutation indicated.
tructural domain. NH2 denotes amino-terminus; COOH, carboxyl-terminus. C, pedigree
erations and numbers. Square indicates male family member; circle, female member;
bol, unaffected member; arrow, proband; “þ”, carrier of the heterozygous missense
Table 3
Phenotypic characteristics of the affected pedigree members alive.
Individual Gender Age (years) Cardiac phenotype LVEDD (mm) LVESD (mm) LVEF (%) LVFS (%) ECG ﬁndings
II-1 M 56 DCM 79 69 34 13
II-6 F 52 DCM, ASD 64 51 31 19 AVB
II-8 F 49 DCM, ASD 64 50 39 20 AVB
III-1 M 30 DCM 56 43 43 22
M denotes male; F, female; DCM, dilated cardiomyopathy; ASD, atrial septal defect; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic
diameter; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; AVB, atrioventricular conduction block.
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are summarized in Table 3.3.3. Multiple alignments of TBX5 protein sequences among various
species
Alignment of multiple TBX5 protein sequences across species
from human to chimpanzee, monkey, dog, cattle, mouse, rat, fowl,
zebraﬁsh and frog showed that the altered serine at amino acid
residue 154 of TBX5 was completely conserved evolutionarily
(Fig. 2).3.4. Reduced transcriptional activity of the mutant TBX5
As shown in Fig. 3, the same amount (0.6 mg) of wild-type and
S154A-mutant TBX5 constructs transcriptionally activated the ANF
promoter by ~10-fold and ~3-fold, respectively (wild type vs
mutant: t¼ 11.0480, p¼ 0.0004), indicating that the S154A-mutant
TBX5 has a signiﬁcantly reduced transcriptional activity compared
with its wild-type counterpart.3.5. Impaired synergistic activation of mutant TBX5 with NKX2-5 or
GATA4
As shown in Fig. 3, when the same amount (0.6 mg) of wild-type
NKX2-5 was cotransfected with wild-type or S154A-mutant TBX5
(0.6 mg), the induced activation of the ANF promoter was ~38-fold
or ~8-fold (wild type vs mutant: t ¼ 22.8218, p ¼ 0.0001); while
in the presence of 0.6 mg of wild-type GATA4, the same amount
(0.6 mg) of wild-type and S154A-mutant TBX5 expression plasmids
activated the ANF promoter by ~22-fold and ~6-fold, respectively
(wild type vsmutant: t¼ 13.5117, p¼ 0.0002). These results suggest
that the mutant TBX5 has an impaired transcriptional activation in
synergy with NKX2-5 or GATA4.Fig. 2. Alignment of multiple TBX5 protein sequences across species. The altered serine at a4. Discussion
In the present study, a novel heterozygous mutation of p.S154A
in TBX5 was identiﬁed in a family with DCM. The missense muta-
tion, which was absent in the 400 reference chromosomes from a
matched control population, co-segregated with DCM in the family
with complete penetrance. A cross-species alignment of multiple
TBX5 protein sequences showed that the altered amino acid was
completely conserved evolutionarily. Biological assays revealed
that the S154A-mutant TBX5 was associated with signiﬁcantly
decreased transcriptional activation alone or in synergy with
NKX2-5 or GATA4. Therefore, it is probable that mutated TBX5
contributes to the pathogenesis of DCM in these mutation carriers.
Human TBX5 is located on chromosome 12q24.1, coding for a
protein with 518 amino acids. The TBX5 protein contains an
important structural motif called T-box, which is highly conserved
throughout members of this family and across species. T-box is
required for speciﬁc DNA binding and proteineprotein interactions,
and previous experiments have demonstrated that TBX5 tran-
scriptionally activates multiple target genes expressed during car-
diac development, including ANF, CX40 and SRF, singly or
synergistically with such cooperative partners as NKX2-5, GATA4
and TBX20 [31]. In the current study, the TBX5 mutation identiﬁed
in DCM patients is located in the T-box and reporter gene analyses
showed that the mutant TBX5 was associated with decreased
transcriptional activity and diminished synergistic activation with
NKX2-5 or GATA4 on a target gene, ANF. These functional data
suggest that haploinsufﬁciency or dominant-negative effect caused
by TBX5 mutation is likely an alternative pathological mechanism
underlying DCM.
The discovery that TBX5 loss-of-function mutation contributes
to DCMmay be partially ascribed to the developmental defects and
remodeling abnormalities of the heart. In humans and vertebrate
animals, TBX5 is highly expressed in the embryonic and adult
hearts, playing a pivotal role in cardiac development and structural
remodeling, including cell type speciﬁcation, cardiomyocytemino acid position 154 of TBX5 is completely conserved evolutionarily among species.
Fig. 3. Functional defects resulted from TBX5 mutation. Activation of atrial natriuretic
factor promoter driven luciferase in COS-7 cells by wild-type TBX5 or S154A-mutant
TBX5 (S154A), alone or in combination with NKX2-5 or GATA4, showed signiﬁcantly
diminished transcriptional activation by the mutant protein. Experiments were per-
formed in triplicate, and mean and standard deviations are shown. An asterisk * in-
dicates p < 0.0005, when compared with wild-type TBX5.
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migration, tissue patterning and morphogenesis [33]. In mice, Tbx5
is expressed in cardiac crescent, linear heart tube, common atrium,
left ventricle, left-side ventricular septum, trabeculae of the right
ventricle, and the atrial aspect of the atrioventricular valves [34].
Homozygous Tbx5-null mice died by E10.5 mainly due to failure of
cardiac looping, hypoplasia of sinuatria and left ventricle. Mice
heterozygous for the deletion of Tbx5 allele suffered from atrial
septal defects, ventricular septal defects, endocardial cushion de-
fects, hypoplastic left heart, aberrant trabeculation, and atrioven-
tricular block, similar to what were observed in patients with Holt-
Oram syndrome [35]. Furthermore, in mice Tbx5 and Gata4 are co-
expressed and interact in the developing atria and ventricles, and
mice doubly heterozygous for Tbx5 and Gata4 displayed embryonic
lethality, thin atrial and ventricular myocardium with reduced cell
proliferation, and atrioventricular septation defects [36]. Addi-
tionally, Tbx5 also physically interacts with other core cardiac
transcriptional factors, including Nkx2-5, Mef2c and Tbx20, and
forms a transcriptional complex resulting in synergistic activation
of multiple downstream genes essential for cardiovascular devel-
opment, including Nppa, Cx40, Srf, Mhy6 and Id2 [31]. Taken
together, these experimental results indicate that mutated TBX5
enhances the susceptibility to DCM in humans.
In addition, loss-of-functionmutations in several transcriptional
cooperators of TBX5, including NKX2-5, GATA4, GATA6 and TBX20,
have been implicated in DCM in humans [23e28]. Therefore,
functionally impaired TBX5 probably increases the vulnerability to
DCM by reducing synergistic activation of target genes.
Previously, mutations inTBX5were reported to cause Holt-Oram
syndrome, an autosomal dominant disorder characterized by
various cardiac anomalies and anterior upper limb malformations.
Cardiac phenotypes comprise a wide spectrum of congenital heart
abnormalities including secundum-type atrial septal defect, ven-
tricular septal defect, atrioventricular septal defect, patent ductus
arteriosus, tetralogy of Fallot, mitral valve defect, and aberrant
pulmonary vein as well as cardiac conduction block and atrial
ﬁbrillation, with atrial septal defect being the most common
[20,21,37]. Clinically, there are three variations of Holt-Oram syn-
drome: patients may have only cardiovascular defects (4%), only
forelimb deformities (27%), or both (69%), and these cardiac and
skeletal malformations vary widely ranging from mild to severe,
even within families [21]. In the present study, in addition to atrial
septal defect and atrioventricular conduction block, DCM was
attributed to a novel TBX5 mutation, thus expanding the pheno-
typic spectrum associated with TBX5.
In conclusion, this study ﬁrstly associates TBX5 loss-of-function
mutation with DCM and provides novel insight into the molecularpathogenesis of DCM, suggesting potential implications in devel-
opment of new preventive and therapeutic strategies for this
commonest primary cardiomyopathy.Conﬂict of interest
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